PMOS to Evaluate the Compliance to Synagis (Palivizumab) Under Daily Pediatrician's Conditions in Premature Infants 33 - 35 wGA Over 2 Consecutive Respiratory Syncytial Virus (RSV) Seasons in Austria
Phase of Trial: Phase IV
Latest Information Update: 17 Jun 2014
At a glance
- Drugs Palivizumab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Sponsors Abbott Laboratories
- 19 Jan 2012 Actual patient number is 124 according to ClinicalTrials.gov.
- 08 Aug 2011 Planned end date changed from 1 Jun 2011 to 1 Apr 2011 as reported by ClinicalTrials.gov .
- 08 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.